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Abstract
Background: A phasic dysregulation of mitochondrial bioenergetics may operate in bipolar disorder, increased in
mania and decreased in depression. We aimed to examine efficacy of two add-on treatments in bipolar depression: N-
acetylcysteine (NAC) and NAC with a combination of nutraceutical agents that may increase mitochondrial biogenesis.
Methods: A three-arm 16-week, double-blind, randomised, placebo-controlled trial, adjunctive to usual treatment, was
conducted. Participants (n = 181) with bipolar disorder and current depressive symptoms were randomised to 2000
mg/day NAC (n = 59), 2000mg/day NAC with the combination nutraceutical treatment (CT, n = 61), or placebo (n = 61).
The primary outcome was change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline
to week 16. Young Mania Rating Scale, Clinical Global Impression (CGI)-Improvement and CGI-Severity scales, Patient
Global Impression scale, Social and Occupational Functioning Assessment Scale (SOFAS), Longitudinal Interval Follow-
Up Evaluation - Range of Impaired Functioning Tool (LIFE-RIFT), and Quality of Life Enjoyment, and Satisfaction
Questionnaire Short Form (Q-LES-Q-SF) were secondary outcomes.
Results: One hundred forty-eight participants had post-randomisation data and were analysed (NAC = 52, CT = 47,
Placebo = 49). No between-group differences were found for the rate of change between baseline and 16weeks on
any of the clinical and functioning variables. Improvements in MADRS, BDRS, SOFAS, and LIFE-RIFT scores from baseline
to the week 20 post-discontinuation visit were significantly greater in the CT group compared to those in the placebo.
At week 20, the CGI-I was significantly lower in the CT group versus placebo. Gastrointestinal symptoms were
significantly greater in the NAC than in the placebo group.
Conclusions: These overall negative results, with no significant differences between groups detected at the
primary outcome but some positive secondary signals, suggest either delayed benefit of the combination or
an improvement of symptoms on withdrawal which warrants further exploration regarding the composition,
mechanisms, and application of mitochondrial agents in illnesses characterised by mitochondrial dysfunction.
Trial registration: ANZCTR (ACTRN12612000830897).
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Background
The pathophysiology of bipolar disorder remains uncer-
tain, but there is evidence of a critical role of mitochon-
drial dysfunction [1]. Phenotypically, bipolar disorder is
a biphasic disorder of energy [2], whereby energy is in-
creased in mania and decreased in the depressive phase.
Both mitochondrial respiration and adenosine triphos-
phate production seem increased in bipolar mania, while
mitochondrial function appears reduced in the depres-
sive or euthymic phase of the disorder [3–5]. It can be
postulated that bipolar disorder involves a phasic dysreg-
ulation of mitochondrial bioenergetics, characterised by
inability to upregulate biogenesis in response to meta-
bolic demands in depression, and to downregulate in
mania [5]. The precise source of this phasic dysregula-
tion remains uncertain, although many operative bio-
logical elements are implicated [4].
Interventions that enhance mitochondrial function
may have the potential to reduce depressive symptoms
in bipolar disorder. Therefore, the aim of this three-arm
study was to examine the efficacy in bipolar depression
of two add-on treatments: N-acetylcysteine (NAC) 2000
mg/day, which has been shown to have potential anti-
depressant and mitochondrial biogenesis effects, and
NAC 2000mg/day together with a “cocktail” of nutrient
agents (a combination nutraceutical treatment [CT] of a
total of 16 compounds that have potential efficacy in in-
creasing mitochondrial biogenesis). The key elements of
the combination comprised acetyl L-carnitine (ALC),
ubiquinone (coenzyme Q10), and alpha lipoic acid
(ALA), in addition to co-factors involved in mitochon-
drial function. The rationale for this combination has
been explicated in detail in a published protocol [6].
We hypothesised that compared to the placebo, both
adjunctive treatments would improve symptoms of de-
pression, based on a change from baseline to week 16
(primary endpoint) in the total score on the Montgo-
mery-Åsberg Depressive Rating Scale (MADRS) as the
primary outcome measure. Secondary outcomes in-
cluded changes from baseline to week 16 and week 20
(4-week post-discontinuation) in the score of overall
symptom severity and improvement (clinician and par-
ticipant rated), quality of life, functional impairment,
and symptoms of mania and anxiety.
Method
Study overview
The study was a 16-week, multi-site, randomised,
double-blind, parallel group trial of a CT, NAC, or pla-
cebo in the depressive phase of bipolar disorder. Partici-
pants received 16 weeks of daily adjunctive treatment with
assessment visits at baseline and 4, 8, 12, 16 (primary end-
point), and 20 weeks (4-week post-discontinuation). A
phone interview at week 2 was conducted to promote
adherence and record any adverse events. Participants
were assigned randomly and consecutively to treatment
with CT, NAC, or placebo (1:1:1 design) in a double-blind
fashion. All participants remained on treatment as usual
(pharmaceutical and complimentary) for the duration of
the trial. The trial was conducted according to the Good
Clinical Practice guidelines. Research ethics commit-
tee approval was obtained at all participating sites
(Barwon Health, The Geelong Clinic, Royal North
Shore Hospital, and The Melbourne Clinic Human
Research and Ethics Committees). The study was reg-
istered on the Australian New Zealand Clinical Trials
Registry (ACTRN12612000830897).
Randomisation and masking
Participant number allocation to treatment arm was
randomly assigned using permutated block random-
isation. The computer-generated randomisation plan
was developed by an independent researcher utilising
four-to-a-block design. Participant numbers were se-
quentially allocated by trial clinicians. To facilitate the
double-blinding process, the trial medications (CT,
NAC only, and placebo) were packed in the medico-
packs and dispensed by an independent pharmacist in
sealed containers. Medicopacks and capsules in all
arms were identical, to conceal treatment allocation
and blinding. The consultant statistician (SC), investi-
gators, and participants were blinded to the group al-
location. Participants were informed and unblinded
via letters sent at the completion of the full study.
Investigational products
All components of the active treatment arms are
well-tolerated by humans at the doses proposed in this
study and are currently available for purchase without
prescription in the USA and Australia. The CT com-
prised N-acetylcysteine (NAC) 2000mg, acetyl L-carni-
tine (ALC) 1000 mg, ubiquinone (Co Q10) 200 mg,
magnesium (as orotate 500 mg) 64mg, calcium ascor-
bate dehydrate (equiv ascorbic acid 200 mg) 242 mg,
cholecalciferol (equiv vitamin D3 250 IU) 12.5μg,
α-tocopherol (equiv natural vitamin E 50 IU) 60 IU,
alpha lipoic acid (ALA) 150 mg, Retinyl palmitate (equiv
vitamin A 3000 IU) 900ugREIU, and vitamin B co-fac-
tors: biotin (vitamin H) (600μg), thiamin hydrochloride
(100 mg), riboflavin (100 mg), nicotinamide (200 mg),
calcium pantothenate (100 mg), pyridoxine hydrochlor-
ide (100 mg), folic acid (800 μg), and cyanocobalamin
(vitamin B12) (800 μg). They were given in the form of
five capsules twice a day, including as follows: four 500
mg NAC capsules, two twice per day; two 500 mg ALC
capsules, one twice per day; two capsules with 75mg
Coenzyme Q10, 75 mg ALA, and 32mg magnesium, one
twice per day; and two capsules with 25 mg Coenzyme
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Q10, and vitamins E, C, A, D3, H, and B, one twice per
day. The other active arm consisted of 2000 mg of NAC
as per the CT arm, in addition to placebo capsules
matched for the remaining CT active capsules. The pla-
cebo arm had matched product for all active capsules,
given in a double-dummy design.
All investigational products were produced under
Pharmaceutical Good Manufacturing Practice. The NAC
and NAC placebo were supplied by Nutrition Care,
Australia. The additional nutraceutical components of
the CT were supplied by BioCeuticals, Australia, with
matching placebos manufactured by Catalent, Australia.
Recruitment procedure
Participants were recruited through their treating clini-
cians and case managers, and self-referral via advertise-
ments (newspaper, online, radio, media via press
releases, and flyers at relevant health and community lo-
cations). Potential participants were contacted and
briefly screened, and a preliminary interview was sched-
uled. All participants provided written informed consent
before enrolment.
Inclusion criteria
Participants (aged 18 years and over) meeting Diagnostic
and Statistical Manual of Mental Disorders IV-TR criteria
for bipolar disorder (I, II, or not otherwise specified) on a
structured clinical interview (Mini-International Neuro-
psychiatric InterviewPlus) with a current acute depressive
episode (MADRS score ≥ 20) were recruited. In addition,
participants must have had the capacity to consent to the
study and comply with study procedures and be using ef-
fective contraception if female, sexually active, and of
childbearing age. Participants currently under any form of
therapy needed to remain on stable therapy for at least 1
month prior to randomisation without significant adjust-
ments to dose. Participants were required to nominate a
current treating physician. If there was a delay of > 7 days
between screening and baseline (randomisation) assess-
ments, or randomisation and medication commencement,
the MADRS was readministered to ensure the participant
still met eligibility criteria (≥ 20).
Exclusion criteria
Exclusion criteria included the following: participants
with a known or suspected active systemic medical dis-
order, recent gastrointestinal ulcers, epilepsy or renal
stones, pregnancy or lactation, or currently taking > 250
mg of NAC, > 250 mg of ALC, > 25 mg of coenzyme
Q10, or > 200μg of selenium/day (a 1-month washout
period was required if participants were taking these
study preparations). Participants currently enrolled in
any other intervention study were excluded. Individuals
treated with warfarin or phenytoin or individuals who
were intolerant to or had an allergic reaction to any
components of the preparation were also excluded.
Withdrawal procedure
Withdrawal from the trial occurred if the participants
ceased taking their trial medication for seven consecu-
tive days, ceased effective contraception, or became
pregnant. Dose changes to existing medications or ther-
apies, or addition or removal of an agent was accepted,
and participants were allowed to continue with the trial.
Participants were withdrawn from the study if they with-
drew consent or at the discretion of the researcher given
adverse events or loss to follow-up.
Measurements
The participants were assessed at baseline using a struc-
tured clinical interview, the Mini-International Neuro-
psychiatric Interview Plus Version 5.0.0. A set of
validated outcome measures was completed at baseline
and weeks 4, 8, 12, 16, and 20 (4 weeks after treatment
discontinuation). These measures included the MADRS
(primary outcome), Hamilton Anxiety Rating Scale
(HAM-A), Bipolar Depression Rating Scale (BDRS),
Young Mania Rating Scale (YMRS), Clinical Global Im-
pression (CGI)-Improvement and CGI-Severity scales,
Patient Global Impression scale (PGI-I), Social and Oc-
cupational Functioning Assessment Scale (SOFAS), Lon-
gitudinal Interval Follow-Up Evaluation - Range of
Impaired Functioning Tool (LIFE-RIFT), and Quality of
Life Enjoyment and Satisfaction Questionnaire Short
Form (Q-LES-Q-SF). Demographic data was collected
including substance use, age, weight, height, sex, psychi-
atric history, and duration of illness. Adherence was
monitored using capsule counts of returned clinical trial
material. Adverse effects were recorded, intervened ac-
cording to medical assessment, and monitored.
Training
Raters had to complete a comprehensive certification
process. All potential raters were required to view the
overview training modules and complete annual reliabil-
ity and inter-rater reliability assessments.
Trial sites
The trial sites included Barwon Health and The Geelong
Clinic in Geelong, The Melbourne Clinic in Melbourne,
and the University of Sydney CADE Clinic based at Royal
North Shore Hospital in Sydney. Recruitment was funded
to take place between March 2013 and August 2015.
Follow-up of adverse events
The research clinician followed up any participant who
completed/withdrew from the study and had an ongoing
adverse event 30 days after trial medication was ceased.
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If a participant withdrew or were withdrawn early from
the study, they were requested to attend a final
face-to-face interview, scheduled to occur as soon as
possible to capture mood symptoms. If the participant
was experiencing an adverse event at that time, they
were arranged to be phoned 30 days later to follow up
that event. If the participant did not attend a final
face-to-face visit upon withdrawal, verbal permission
was sought for a final monitoring phone call (30 days
post-discontinuation). Participants who had an ongoing
adverse event that was concerning them were asked to
contact their general practitioner or treating physician.
Statistical power
Overall power to detect significant differences was
between the actual patterns of the means. Assuming a
correlation of post-treatment scores with baseline mea-
surements of 0.70 and an effect of the dosage such that
either group (NAC and CT) differs from the placebo by
0.75 standard deviations, power will be maintained
above 90% with 75 subjects in each group. Pairwise
comparisons with 75 subjects per group in the three
groups would enable effects smaller than 0.6 standard
deviations to be detected with power of 80%. These ef-
fect sizes are in the small to moderate range. The experi-
ment would thus be capable of detecting differences
between groups of clinical and scientific interest with a
total sample size of 225.
Data analysis
The baseline characteristics of the cohort were examined
using basic descriptive statistics such as means and
standard deviations for continuous measures and fre-
quencies and percentages for categorical variables. To
determine differences between completers (data col-
lected at more than one post-randomisation time point)
and non-completers (no post-randomisation data), a
series of independent samples t tests and chi-square (χ2)
analyses were conducted.
For the analysis of primary and secondary outcomes, a
modified intent-to-treat approach (mITT) was used with
analysis on those with post-randomisation data. For the
analysis of the primary outcome of severity of depressive
symptoms (MADRS), a mixed model repeated measures
(MMRM) was used. Within this model, the fixed effects
were group (Placebo, NAC, CT), time (0, 4, 8, 12, 16,
and 20 weeks), and site (Geelong, Melbourne, Sydney).
The interaction between group and time was also exam-
ined. The MMRM includes a random intercept and
slope over time. The relationships between observations
across the six time points were modelled using unstruc-
tured covariance matrix. For the primary analyses, the
focus was on planned comparisons that determined
whether the rate of change from baseline to 16 weeks
(primary end point at end of treatment) and from base-
line to 20 weeks (post-discontinuation) differed among
the groups. The planned comparisons were done to
compare a treatment group (either NAC or CT) against
the placebo; there was no comparison of the two active
treatment groups as the focus was on exploring the bene-
fits of both treatments independently versus the placebo.
To examine group differences on the CGI-Improvement
(CGI-I) and PGI-I at 16 and 20weeks, one-way analysis of
variance models were conducted, followed by two planned
comparisons comparing the two active treatments to the
placebo group. To examine differences between the
groups with respect to adverse events, chi-square (χ2) ana-
lysis was conducted; significant χ2 values were followed by
Bonferroni post hoc comparisons for proportions.
Results
Sample characteristics
Participants (N = 181) who met inclusion criteria were
randomised to one of the three groups: n = 59 in the
NAC group, n = 61 in the CT group, and n = 61 in the
placebo group. 58.6% (n = 106) had a diagnosis of bipolar
disorder I (BDI) and 41.4% (n = 75) had bipolar disorder
II; 60.7% (n = 37) of each of the CT and placebo groups
had a diagnosis of BDI whereas 54.2% (n = 37) in the
NAC group had a diagnosis of BDI. 38.7% (n = 70) were
recruited at the Melbourne site, 34.8% (n = 63) at the
Sydney site, and 26.5% (n = 48) were recruited from Gee-
long. The baseline characteristics of this cohort are
shown in Table 1. Participants were aged between 19.6
and 72.0 years (M= 45.5, SD = 12.3). The majority were
female (63.5%, n = 115) and were not married or in a de
facto relationship (54.1%, n = 98).
With respect to the physical health, 16.1% (n = 29) re-
ported having a current endocrine problem, 12.8% (n = 23)
have a current cardiovascular problem, and gastrointes-
tinal problems were reported in 21.0% (n = 38) of the co-
hort. Approximately a third of the cohort currently
smoked (32.6%, n = 59), and 56.4% (n = 102) consumed al-
cohol on a regular basis. The rate of alcohol use disorders
(abuse or dependence) was 42.0% (n = 76). Current illicit
drug use was reported in 13.8% (n = 25).
The average age of first symptoms was 19.3 years (SD
= 8.8), and the average age of formal diagnosis was at
35.2 years (SD = 11.3). The mean duration of illness was
24.9 years (SD = 11.8), with the majority (43.1%, n = 78)
having had between 2 and 10 hospital admissions. Most
participants (63.8%, n = 104) had experienced 20 or more
lifetime depressive episodes.
The medications prescribed at baseline included mood
stabilisers (68.5%, n = 124), antipsychotics (58.6%, n = 106),
antidepressants (55.8%, n = 101), and benzodiazepines
(24.9%, n = 45). Regarding baseline mood stabiliser status,
combining the three medications, 93.4% (n = 169) were on
Berk et al. BMC Medicine           (2019) 17:18 Page 4 of 11
at least one of the medication types, lithium, mood
stabiliser, and/or antipsychotic. There were no differ-
ences between the groups: placebo 88.5% n = 54, NAC
94.9% n = 56, and CT 96.7% n = 59. Other nutraceuti-
cals (nutrient or herbal medicines) had been used by
43.1% (n = 78) of the cohort. About a quarter of the
cohort had regular psychotherapy with a psychologist
or a psychiatrist. The cohort had moderate levels of
depression and anxiety, overall psychopathology, and
moderate-severe impairment in social and occupational
functioning (details are shown in Table 2). The most com-
monly reported comorbidities were social anxiety disorder,
obsessive compulsive disorder, and panic disorder.
There were no significant differences between the pla-
cebo and the two treatment arms on any of the demo-
graphic characteristics detailed in Table 1. There were
no differences noted on any of the clinical measures
depicted in Table 2.
Table 1 Descriptive statistics describing the baseline demographic and illness features for the three groups
Note: NAC, N-acetyl cysteine; CT, combination nutraceutical treatment
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Completer analysis
Of the 181 cases that were randomised, 81.8% (n = 148)
had post-randomisation data and were included for ana-
lysis (see Fig. 1). The CT had the highest proportion of
cases with no post-randomisation data (23.0%, n = 14),
followed by the placebo group (19.7%, n = 12) and NAC
group (11.9%, n = 7); however, these differences between
groups were not significant.
Of the 148 participants who had post-randomisation
data, 77.7% (n = 115) had data at the primary endpoint
of week 16; 81.6% (n = 40) in the placebo, 76.9% (n = 40)
in NAC, and 74.5% (n = 35) in the CT group. The reten-
tion of participants at week 20 was also good at 73.6%
(n = 109), with no loss of participants in the placebo
group, 71.2% (n = 37) in the NAC, and 68.1% (n = 32) in
the CT group. The groups did not differ significantly
with respect to retention rates at weeks 16 and 20. Re-
garding completer analyses, there were significant differ-
ences between those who did and did not have data at
the primary endpoint of week 16 and final endpoint
week 20 in terms of age of diagnosis (week 16 no data
M = 31.5, SD = 10.1; data M = 36.4, SD = 11.5; t(144) =
− 2.19, p = .030: week 20 no data M = 31.8, SD = 9.5;
data M = 36.6, SD = 11.7; t(144) = − 2.27, p = .025) and
use of mood stabilisers (week 16 no data 48.5%, n = 16;
data 74.8%, n = 86); χ2 (1) = 8.28, p = .004: week 20 no data
51.3%, n = 20; data 75.2%, n = 82; χ2 (1) = 7.69, p = .006).
Primary outcome—depressive symptoms on MADRS
The interaction between group and time (from base-
line to week 20) for the MADRS was not significant,
F(10, 120.8) = 1.17, p = .315; however, the main effect
for time was significant, F(5, 120.9) = 74.43, p < .001,
indicating that all groups had improvement in depres-
sive symptoms over the duration of the trial. Examin-
ation of planned comparisons revealed that there was
a significant difference between the placebo and CT groups
with the CT group demonstrating a greater reduction in
MADRS scores from baseline to week 20 than the placebo,
(Mdiff = − 5.2, SEdiff = 2.4), t(111.5) = − 2.19, p = .031 (see
Fig. 2 for estimated means for each group over the time,
see Table 3 for mean change scores). Post hoc comparison
indicated that at the 20-week post-discontinuation visit,
the CTgroup had a significantly lower MADRS score com-
pared to the placebo, p = .046.
Secondary outcomes
The omnibus interactions for group by time for the
BDRS, HAM-A, YMRS, CGI, SOFAS, LIFE-RIFT, and
Q-LES-Q were all not significant; however, for all of the
variables with exception of the YMRS, the time main ef-
fects in the models were significant (all p < .001), indicat-
ing all groups improved over time. With the planned
comparisons, the rate of change between baseline and
week 20 was significantly greater for the CT as com-
pared to the placebo group for the BDRS, Mdiff = − 4.82,
SEdiff = 2.30, t(113.0) = 2.09, p = .039, the SOFAS, Mdiff =
6.25, SEdiff = 2.84, t (115.9) = − 2.20, p = .030, and the
LIFE-RIFT, Mdiff = − 2.00, SEdiff = 0.94, t(120.0) = − 2.13,
p = .035. The differences between the CT and placebo
groups at 20 weeks on these variables were not significant
(BDRS, p = .060; SOFAS, p = .083; LIFE-RIFT, p = .158). In
Fig. 2, there appeared to be a separation of the groups on
the YMRS in the early phase of the trial. On the YMRS,
the difference between the placebo and CT groups was
significantly different at the 4-week time point (p = .037);
however, when adjusted for multiple comparisons between
the groups at every time point using Bonferroni, the com-
parison is no longer significant (p = .111).
Table 4 documents differences between the three
groups with respect to CGI-I and PGI-I. For the CGI-I,
there was a significant difference between the placebo
Table 2 Baseline clinical characteristics for the three groups
Note: NAC, N-acetyl cysteine; CT, combination nutraceutical treatment; MADRS, Montgomery-Åsberg Depression Rating Scale; BDRS, Bipolar Depression Rating
Scale; YMRS, Young Mania Rating Scale; HAM-A, Hamilton Anxiety Rating Scale; CGI-S Clinical Global Impressions - Severity Scale; ; SOFAS, Social and Occupational
Assessment Scale; LIFE-RIFT, The Range of Impaired Functioning Tool; Q-LES-Q, Quality of Life
Berk et al. BMC Medicine           (2019) 17:18 Page 6 of 11
and CT groups at 20 weeks, t(106) = 2.08, p = .040. No
other differences were noted.
Adverse effects
Adverse events (AEs) were categorised into the following
categories: behavioural, gastrointestinal, musculoskeletal,
neurological, respiratory, and other (see Table 5). Gastro-
intestinal problems were the most frequent AE noted in
the cohort; 38.5% (n = 39) reported heartburn/reflux/in-
digestion, 17.8% (n = 18) had diarrhoea/loose stools, and
15.8% (n = 16) had nausea/vomiting. There were signifi-
cant differences between the three groups with respect
to gastrointestinal, χ2 (2) = 9.98, p = .007, and other AEs,
χ2 (2)=7.14, p = .028. The number of participants report-
ing gastrointestinal issues in the NAC group was signifi-
cantly higher than that in the placebo group, p < .05.
The number of participants reporting other com-
plaints was significantly higher in the placebo than in
the CT group, p < .05. Closer examination indicated
that the group difference in gastrointestinal problems
was due the NAC group having significantly higher
heartburn/reflux/indigestion than both other groups
(both p < .05). No other significant differences were
found.
In the CT arm, 20 participants (33%) reported 26
events (17 elevation, 9 hypomania/mania); in the NAC
arm, 13 participants (22%) reported 19 events (13 eleva-
tion, 6 mania/hypomania), and in the placebo arm, 14
participants (23%) reported 17 events (11 elevation, 6
hypomania/mania). Of these, four were serious AEs re-
lated to hospitalisation for mania/hypomania (2 in the
placebo and 2 in the NAC groups).
Fig. 1 CONSORT flowchart depicting participant flow through the trial
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Discussion
The study provided a number of novel findings despite
having an overall negative outcome as a trial. First, nei-
ther the combination of mitochondrial-modifying nutri-
ent agents nor NAC alone separated from the placebo at
the primary endpoint of the study; hence, the study is
essentially negative on the primary outcome variable of
symptom severity as measured by the MADRS. No sig-
nificant between-group differences were observed on
change scores from baseline to week 16 on any of the
other clinical and functioning measures.
Second, the rate of change between baseline and week
20 post-discontinuation was significantly greater in the
CT group compared with the placebo on a number of
measures including depression, both BDRS and MADRS,
and functioning. At the 20-week post-discontinuation,
clinical improvement was significantly greater in the CT
group compared to that in the placebo. This suggests
Fig. 2 Estimated means (±SE) derived from MMRM for each of the clinical measures for the three groups and over the six time points. Note:
YMRS, Young Mania Rating Scale; CGI-BP Clinical Global Impressions Scale - Bipolar; BDRS, Bipolar Depression Rating Scale; MADRS, Montgomery-
Asberg Depression Rating Scale; Brief Psychiatric Rating Scale, BPRS; GAF, Global Assessment of Functioning ; SOFAS, Social and Occupational
Assessment Scale; QLS, Quality of Life Scale; NAC N-acetylcysteine; CT Combination Treatment
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either delayed benefit of the combination or an improve-
ment of symptoms on withdrawal which warrants fur-
ther exploration.
Second, the CT group had higher levels of manic
symptoms at week 4 compared to the placebo. While
this may reflect a type 1 error and did not survive cor-
rection for multiple comparisons, this finding provides
very tentative evidence that while CT may drive mito-
chondrial biogenesis, this also may have the undesirable
effect of worsening manic symptoms without a corres-
pondingly robust decrease in depressive symptoms.
Third, NAC alone failed to separate from the placebo on
the primary mood outcome in contrast to the only pre-
vious study in bipolar disorder [7], and a number of
other studies in depression, PTSD, and substance abuse
[8–10]. Whether this reflects a true null effect or is a
consequence of latent methodological factors remains
uncertain. The rates of substance use were significantly
higher in the CT group which may have adversely influ-
enced outcomes in that group, as substance abuse pre-
dicts poorer outcomes. Critically, in the 2008 bipolar
disorder study, NAC did not separate from the placebo
at week 16—the endpoint of this study, and only sepa-
rated at weeks 20 and 24, which suggest a delayed
effect. There may be other patient or methodological
differences between the studies that may explain these
discordant findings. It is true both that many initially
positive studies are not replicated, and equally many
known efficacious agents carry the baggage of negative
studies. A powerful operative factor driving null out-
comes in depression studies in developed healthcare
systems is “service filters”, since participants volunteer-
ing for clinical trials at tertiary treatment centres tend
to self-select on the basis of treatment resistance and
poor outcomes with conventional treatments and tend
to be more burdened by psychological, social, and per-
sonality comorbidity.
Other methodological considerations need to be borne
in mind in interpreting these data. The composition of
the mitochondrial combination was based on a synthesis
of the extant literature, which is by its nature, prelimin-
ary and incomplete. It is probable that more extensive
pre-clinical data could result in an improved or, indeed,
efficacious combination. Addition of other mitochond-
rially active agents such as creatine or resveratrol, or al-
tered doses of the composition may have altered the
study findings. The sample size of 181 resulting in arms
with 59–61 participants each is capable of detecting
Table 3 Estimated mean change (±SE) from MMRMs for baseline to week 16, and baseline to week 20, for the three groups on
clinical measures
Note: YMRS, Young Mania Rating Scale; CGI-BP Clinical Global Impressions Scale - Bipolar; BDRS, Bipolar Depression Rating Scale; MADRS, Montgomery-Asberg
Depression Rating Scale; Brief Psychiatric Rating Scale, BPRS; GAF, Global Assessment of Functioning ; SOFAS, Social and Occupational Assessment Scale; QLS,
Quality of Life Scale
Table 4 Differences between NAC and Placebo and CT versus Placebo on the clinical and patient measures of improvement
Note: CGI-I, Clinical Global Impressions - Improvement; PGI-I, Patient Global Impression - Improvement
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moderate but not small effect sizes. In both unipolar and
bipolar depression, most efficacious agents have small
effect sizes, which this study may not have been able to
detect. The a priori power estimate was a sample of 225,
but this study recruited 181 individuals. The study dur-
ation is likely an issue. As the positive previous study of
NAC was significant at the week 20 and 24 time points
[7], not at the earlier week 16 time point, this study is
likely to have been too short for differences to be appar-
ent. A new study in schizophrenia separated on negative
symptoms at 12 but not 6 months, suggesting that NAC
is extremely slow for benefit to manifest. Those who had
more stable mood stabiliser treatment were more likely
to be retained in the trial. Finally, the placebo group
demonstrated a mean change in the MADRS of almost
15 points. Large placebo responses are associated with a
lower likelihood of showing a superiority of the active
drug in clinical trials of bipolar disorder [11]. Modifiable
factors associated with a higher placebo response, rele-
vant to our study, include a lower probability of receiv-
ing the placebo and longer study duration [12, 13].
A further conclusion of the study is that the benign
nature of nutraceutical approaches cannot be assumed.
It is a popular view that such approaches are without
risk. Yet, the possible increase in manic symptoms in
this study may suggest otherwise. Any agent with neuro-
biological properties has the potential for these to be ad-
verse as well as beneficial. However, the study opens the
door to the utilisation of similar therapeutic strategies in
other disorders characterised by impaired mitochondrial
biogenesis, where the risks of mood elevation are min-
imal, such as chronic fatigue syndrome. Biomarker
stratification has the promise of assisting with targeted
therapy against identified targets, with preliminary albeit
inconclusive leads to date [14].
Conclusion
In summary, this study produced unexpected data on
the potential efficacy of NAC and CT for the treatment
of bipolar depression. While negative on the primary
16-week outcome, as measured by the MADRS, there
was statistical separation on a number of measures at
the 20-week post-discontinuation visit, which was offset
by a possible increase in manic symptoms, as measured
by the YMRS. Though this study does not provide a
clear pathway to treat bipolar depression by augmenting
mitochondrial function, it does furnish us with proof of
principle and points to a mechanistic role of increased
biogenesis in the pathophysiology of mania.
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